| Document |
Document Title |
|
WO1999063939A9 |
Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 l...
|
|
WO/2001/025193A1 |
Phenolic compounds of general formula (I); and recording materials characterized by containing one of them and exhibiting high light stability wherein R?1¿ and R?2¿ are each hydrogen or C¿1-6? alkyl; m is an integer of 1 to 6; n is an...
|
|
WO/2001/023347A1 |
The present invention relates to novel compounds of general formula (I), pharmaceutical formulations comprising these compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or preventio...
|
|
WO/2001/023088A1 |
The invention relates to a catalyst for asymmetrical transfer hydrogenation on the basis of a transition metal compound and a nitrogen-containing enantiomerically enriched ligand. The invention also relates to various processes for the p...
|
|
WO/2001/023082A2 |
This invention provides enhanced attachment of chemical moieties to the surface of an electronically addressable microchip array permeation layer. The attachment of the chemical moieties may occur at predetermined locations of the array ...
|
|
WO/2001/023350A1 |
Thioalkylamine derivatives represented by general formula (I); and a process for the preparation thereof wherein R¿1? and R¿2? are each H, (C¿1-4?)alkyl, (C¿3-8?)cycloalkyl, (C¿3-8?)cycloalkyl(C¿1-4?)alkyl, (substituted) phenyl, (s...
|
|
WO/2001/023349A1 |
Acylsulfonamide derivatives represented by general formulae (I) and (II); and chymase inhibitors and therapeutic and/or preventive drugs for hypertension or the like, containing the same as the active ingredient.
|
|
WO/2001/023351A1 |
The present invention provides a novel fluorochemical oligomer, and polymer composition comprising the fluorochemical oligomeric compound and a thermoplastic or thermoset polymer. The polymer composition is useful in preparing shaped art...
|
|
WO/2001/023356A1 |
The invention relates to novel substituted N-phenyl-phenoxy nicotinic acid-(thio)amides of general formula (I) in which: Q represents O (oxygen) or S (sulfur); R?1¿ represents hydrogen or optionally substituted alkyl, alkenyl or alkynyl...
|
|
WO/2001/021584A1 |
The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
|
|
WO/2001/021575A1 |
The present invention relates to compounds of the general formula: NO¿2?-A-B wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 carbon atoms and B is (CH¿2?)¿n?(COOH)¿m? in which n is an integer from 0 to 2 and m is a...
|
|
WO/2001/021583A1 |
Hydroxamic acid derivatives represented by general formula (I), nontoxic salts thereof or prodrugs of the same (wherein each symbol is as defined in the description). Because of inhibiting the production of IL-6, the compounds of the gen...
|
|
WO/2001/021578A1 |
o-Anisamide derivatives which serve as peroxisome proliferator-activated receptor (PPAR) agonists, in particular human PPAR agonists, and are efficacious in preventing and/or treating metabolic diseases in which they participate (hyperli...
|
|
WO/2001/021172A1 |
The present invention relates to pharmaceutical compositions comprising, as an anti-cancer agent: (a) one or more compounds having the formula NO¿2?-A-B, wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 double bonds, a...
|
|
WO/2001/021576A1 |
Aromatic diamide derivatives represented by general formula (I) or salts thereof and agricultural/horticultural chemicals containing the same as the active ingredient, wherein A?1¿ represents alkylene, alkenylene or alkynylene; B repres...
|
|
WO/2001/019778A1 |
The invention relates to the use of compounds of formula (I) and of their salts and stereoisomers in the production of medicaments for treating cardiovascular diseases.
|
|
WO/2001/019724A2 |
The present invention relates to a novel aromatic polysulfide and an asphalt composition containing the same, and more particularly, to a novel aromatic polysulphide having repeating units of formula (I), an asphalt composition, an aspha...
|
|
WO/2001/019808A1 |
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2001/019796A1 |
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2001/019780A2 |
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof used in the production of medicaments for the treatment of cardiovascular diseases.
|
|
WO/2001/019776A2 |
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof used to produce medicaments for the treatment of cardiovascular diseases.
|
|
WO/2001/019771A1 |
Disclosed is a process for the preparation of aryl carboxylate esters by the reaction of a phenol reactant with an esterification agent selected from carboxylic acid anhydrides and carboxylic acid halides in the presence of trifluoroacet...
|
|
WO/2001/017982A1 |
The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.
|
|
WO/2001/018171A2 |
The present invention provides the compound having formula (I), wherein each of R¿1? and R¿2? is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or p...
|
|
WO/2001/017953A1 |
The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the growth or regeneration of neuronal cells. In ...
|
|
WO/2001/017955A2 |
A compound of formula (I) wherein: R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿ and R?7¿ are as defined within; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I)...
|
|
WO/2001/017973A2 |
The invention relates to compounds of formula (I), wherein the substituents have the meaning cited in Claim (1). Said compounds are suitable for utilization as herbicides.
|
|
WO/2001/017972A2 |
The invention relates to novel compounds of formula (I), wherein the substituents have the significance cited in claim (1) and the agronomically compatible salts, isomers and enantiomers of said compound, which are suitable for use as he...
|
|
WO/2001/017956A1 |
A compound of formula (I) wherein: n is 1 or 2; R?1¿ is chloro, fluoro, bromo, methyl or methoxy; R?2¿ is as defined within; R?3¿ is as defined within; and R?4¿ is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vi...
|
|
WO/2001/016057A1 |
The invention relates to a process for the preparation of biphenyls or aromatic olefins by means of coupling reactions of the Suzuki coupling and Heck coupling types using allylpalladium catalysts of the $g(m)-halo(tri-tert-butylphosphin...
|
|
WO/2001/016098A1 |
Novel thioglycerol derivatives, processes for their manufacture, and optical materials made from such compounds. The thioglycerol derivatives have high concentrations of sulfur relative to compounds conventionally used for optical materi...
|
|
WO/2001/016097A1 |
The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzy...
|
|
WO/2001/014310A1 |
Pleuromultilin $g(b)-ketoesters of Formula (IA) or (IB), in which R?1¿ is a nitrogen containing heterocycle, an optionally substituted aryl or optionally substituted heteroaryl group, or CH¿2?R?5¿; R?2¿ is vinyl or ethyl; R?3¿ is H,...
|
|
WO/2001/014316A1 |
A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.
|
|
WO/2001/012587A1 |
The invention relates to known and novel acylaminosalicylic acid amides, to several methods for producing them and to their use for combating organisms that are harmful to plants, and to novel intermediate products and methods for produc...
|
|
WO/2001/012595A1 |
A process for producing aromatic disulfides represented by the following general formula (II): Yn-Ar-S-S-Ar-Yn wherein Ar represents an aromatic hydrocarbyl ring; Y represents a monovalent electron attractive group and when n is 2 or mor...
|
|
WO/2001/010776A1 |
A process is provided for the combustion of ammonium salts of sulfuric acid contained in aqueous media. More particularly, a reductive combustion process which produces a combustion gas containing a divalent sulfur compound having a high...
|
|
WO/2001/010825A1 |
Novel bactericides having an excellent controlling effect on plant disease injury (in particular, wheat powdery mildew and cucumber gray mold) without exerting any undesirable effect on crops. Carbamate derivatives represented by general...
|
|
WO/2001/010828A1 |
Disclosed are SNACE derivatives of general formula (I), wherein n= 1 or 2, x = 0, 1 or 2, R¿1? is an alkyl radical (C¿1-22?) and R¿2? is an acyl radical (C¿2-22?) or an O-acetyl salicyl radical. Said derivatives are used as pharmacol...
|
|
WO/2001/009221A1 |
The invention relates to compounds of formula (Ia) or (Ib). In said formulas, A represents an aliphatic, cycloaliphatic, araliphatic or aromatic radical of the value (n + 1) and n is a whole number from 0 to 5, E represents an aliphatic,...
|
|
WO/2001/008672A2 |
N-Substituted glucamine compounds of Formula (I) are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula (I) may be used alone, or in combinati...
|
|
WO/2001/009088A1 |
Urea and thiourea derivatives inhibit cell function of the chemokine receptor CCR-3. These compounds offer an effective means for treating a range of diseases thought to be mediated by the CCR-3 receptor. A variety of useful urea and thi...
|
|
WO/2001/009095A1 |
A compound of formula (I) wherein R¿2? is arylene or heterocyclene; or R and R¿2? together with the nitrogen atom to which they are attached form non-aromatic heterocyclene; and the other residues have various meanings, useful as pharm...
|
|
WO/2001/007400A1 |
Substances inhibiting cell adhesion mediated by adhesion molecules (in particular, VLA-4) which enable the prevention and treatment of inflammatory diseases caused by leukocyte (for example, monocyte, lymphocyte or eosinocyte) infiltrati...
|
|
WO/2001/005756A1 |
Compounds which are 3-arylsulfonyl-2-methyl propanoic acid derivatives of formula (I): wherein X is HO-NH- or HO-, R¿1? is selected from phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, benzamido (i.e., -NH-CO-Ph) and benzamido su...
|
|
WO/2001/005742A1 |
The invention concerns drug precursors with antimalarial effect, characterised in that it consists in quaternary bis-ammonium salts of general formula (I) wherein A and A', identical or different, are respectively either a group A¿1? an...
|
|
WO/2001/005743A1 |
The invention relates to substituted 3-amino-2-benzyl-1-phenyl-propane derivatives, to methods for producing them, to medicaments containing these compounds and to the use of these substances for producing medicaments.
|
|
WO/2001/005793A1 |
The present invention is substituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (X) and unsubstituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (XI) such as the compounds of EXAMPLE (13), which are useful in ...
|
|
WO/2001/005748A1 |
The current invention discloses novel oligomeric amidino aminocarboxylate derivatves useful as nitric oxide synthase inhibitors.
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
